Therapy-related acute promyelocytic leukemia: Further insights into the molecular basis of the disease and showing the way forward in therapy

Leukemia and Lymphoma

Volumn 50, Issue 7, 2009, Pages 1073-1074

  Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GYRASE INHIBITOR; IDARUBICIN; MITOXANTRONE; RETINOIC ACID;

ADVANCED CANCER; BREAST CANCER; CARDIOTOXICITY; CHROMOSOME 11Q; CHROMOSOME TRANSLOCATION; DNA DAMAGE; DRUG CHOICE; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG USE; GENETIC PREDISPOSITION; GENOMIC INSTABILITY; HODGKIN DISEASE; HUMAN; LEUKEMIA REMISSION; MOLECULAR GENETICS; MULTIPLE SCLEROSIS; NOTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SECOND CANCER;

ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MEDICAL ONCOLOGY; NEOPLASMS, SECOND PRIMARY; OXIDES; TRANSLOCATION, GENETIC; TREATMENT OUTCOME; TRETINOIN;

EID: 68449088873     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902995655     Document Type: Note

References (13)

1. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994;83:2780-2786.
2. Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: The GIMEMA experience. Blood 2002;100:1972-1976.
3. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123-2137.
4. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529-1538.
5. Hasan SK, Mays AN, Ottone T, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008;112:3383-3390.
6. Aversa SML, Trentin C, Sorarů M, et al. Acute promyelocytic leukemia after Stanford V plus radiotherapy for advanced Hodgkin lymphoma. Leuk Lymphoma 2009;50:1214-1216.
7. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-3860.
8. Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 2006;107:2627-2632.
9. Alimoghaddam K, Shariftabrizi A, Tavangar SM, et al. Antileukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia. Leuk Lymphoma 2006;47:81-88.
10. Ravandi F, Estey E, Jones D, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009;27: 504-510.
11. Ammatuna E, Montefusco E, Pacilli M, et al. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone. Leuk Lymphoma 2009;50:1217-1218.
12. Andersen MK, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 2002;100: 1928-1929; author reply 1929, 2002.
13. Garcia-Manero G, Kantarjian HM, Kornblau S, Estey E. Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 2002;16:1888.